Concentrated growth factor inhibits UVA-induced photoaging in human dermal fibroblasts via the MAPK/AP-1 pathway

Meng Zhang, Tai Zhang, Yanan Tang, Guiyun Ren, Yanning Zhang, Xiangyu RenBioscience 2020 · DOI

TL;DR

This study investigates how Concentrated Growth Factor (CGF) protects human skin cells from UVA-induced photoaging. Researchers found that CGF reduces oxidative stress and inhibits a key signaling pathway (MAPK/AP-1) that leads to the degradation of skin's structural components, offering a potential new strategy for preventing skin aging.

What Problem Does This Paper Address?

The paper addresses the problem of skin photoaging, which is primarily caused by long-term exposure to ultraviolet (UV) radiation from the sun. UVA radiation, in particular, penetrates deep into the dermis and damages the extracellular matrix, leading to wrinkles, loss of elasticity, and other signs of aging. This damage is mediated by oxidative stress, which triggers the production of matrix metalloproteinases (MMPs) that break down collagen and other structural proteins. Current treatments for photoaging often have limitations. This study explores the potential of Concentrated Growth Factor (CGF), a novel biomaterial derived from blood platelets, as a protective agent against UVA-induced photoaging and aims to elucidate its underlying mechanism of action.

Methods

The researchers utilized a multi-pronged approach to investigate CGF's effects on human dermal fibroblasts (HDFs) exposed to UVA radiation:

  • Cell Culture: Primary HDFs were isolated from human facial skin.
  • UVA Irradiation: HDFs were exposed to varying doses of UVA radiation to determine an optimal dose for inducing photoaging.
  • CGF Treatment: Cells were treated with different concentrations of CGF to identify the most effective concentration.
  • Cell Viability Assay (MTT): This standard assay was used to measure the metabolic activity of cells, indicating their viability and proliferation after UVA exposure and CGF treatment.
  • Reactive Oxygen Species (ROS) Detection:
    • Immunofluorescence Assay: Visualized ROS levels within cells.
  • Flow Cytometry: Quantified the average fluorescence intensity of ROS in cell populations.
  • Gene Expression Analysis (RT-PCR): Measured the mRNA levels of key proteins involved in photoaging, specifically MMP-1, c-Jun, and P38.
  • Protein Expression Analysis (Western Blot): Determined the protein levels of MMP-1, c-Jun, and P38.
  • Morphological Observation: Microscopic examination of HDFs to assess changes in cell shape and integrity following treatments.

Datasets

Not discussed in the paper. The study utilizes primary cell cultures derived from human skin tissue.

Key Insights and Ideas

  • CGF as a Protective Agent: The study strongly suggests that CGF can effectively protect HDFs from UVA-induced damage, improving cell viability and mitigating the negative morphological changes associated with photoaging.
  • Mechanism of Action - ROS Reduction: A key finding is that CGF significantly reduces the production of reactive oxygen species (ROS) induced by UVA radiation. This is crucial because ROS are primary drivers of oxidative stress and subsequent cellular damage in photoaging.
  • MAPK/AP-1 Pathway Inhibition: The research identifies the MAPK/AP-1 signaling pathway as a critical target of CGF's protective effects. CGF was shown to inhibit the expression of key components of this pathway, namely P38 and c-Jun, at both mRNA and protein levels.
  • Downstream Effect - MMP-1 Inhibition: By inhibiting the MAPK/AP-1 pathway, CGF effectively reduces the expression of MMP-1. MMP-1 is a major collagenase responsible for degrading the extracellular matrix, a hallmark of photoaging. This finding links CGF's action to the prevention of collagen breakdown.
  • Clinical Relevance: The findings provide a strong theoretical basis for using CGF as a potential therapeutic or preventative strategy for skin photoaging, offering a novel clinical approach.

Key Results

  • UVA Dose-Response: UVA irradiation significantly reduced HDF viability in a dose-dependent manner, with 20 J/cm² identified as a suitable dose for inducing photoaging in the study.
  • Optimal CGF Concentration: 20% CGF was determined to be the optimal concentration for enhancing cell viability in UVA-treated HDFs.
  • ROS Reduction: UVA irradiation significantly increased intracellular ROS levels in HDFs. CGF treatment effectively rescued this increase, reducing ROS levels back towards control levels.
  • Gene Expression Modulation: UVA irradiation significantly upregulated the mRNA expression of P38, c-Jun, and MMP-1. CGF treatment significantly decreased these upregulated mRNA levels.
  • Protein Expression Modulation: Similarly, UVA irradiation increased the protein expression of P38, c-Jun, and MMP-1. CGF treatment significantly reduced these protein levels compared to the UVA-treated group.
  • Morphological Improvement: UVA-irradiated HDFs showed signs of swelling, rounding, and rupture. CGF treatment helped restore a more regular cell morphology and reduced the number of atrophied and suspended cells.

Limitations and Future Work

  • In Vitro Study: The study was conducted in vitro using cultured HDFs. While promising, further in vivo studies are needed to confirm these findings in a more complex biological system and to assess CGF's efficacy and safety in living skin.
  • Mechanism Elucidation: While the study identifies the MAPK/AP-1 pathway as a key target, further research could explore other potential mechanisms by which CGF exerts its protective effects.
  • Clinical Application: The paper suggests CGF as a new clinical strategy. Future work would involve clinical trials to evaluate its therapeutic potential and long-term effects in human subjects.
  • Specific UVA Wavelengths: The study focused on UVA radiation. Future research could investigate the effects of CGF on UVB-induced damage or a combination of UV wavelengths.

Summary updated

Abstract

Ultraviolet (UV) radiation-induced photoaging is one of the contributors to skin aging. UV light triggers oxidative stress, producing a large number of matrix metalloproteinases (MMPs) and degrading the extracellular matrix in skin cells, thereby causing a series of photoaging symptoms. Concentrated growth factor (CGF) is a leukocyte- and platelet-rich fibrin biomaterial that plays a protective role in the occurrence and development of skin photoaging. In the present study, we investigated the underlying mechanism of CGF in the UVA-induced photoaging of human dermal fibroblasts (HDFs). A primary culture of HDFs was isolated from normal human facial skin. The cells were treated with CGF following UVA radiation. Proliferation of cells was detected using MTT assay, followed by measurement of reactive oxygen species (ROS) using immunofluorescence assay and flow cytometry. The mRNA and protein expression levels of P38, c-Jun, and MMP-1 were detected using real-time polymerase chain reaction and Western blot, respectively. CGF was found to improve cell viability by inhibiting the production of ROS and reducing oxidative damage. In addition, there was lower expression of p38 and c-Jun at the mRNA and protein levels following CGF treatment, thus resulting in the inhibition of MMP-1 expression. Our results suggest that CGF could protect HDFs against UVA-induced photoaging by blocking the P38 mitogen-activated protein kinase/activated protein-1 (P38MAPK/AP-1) signaling pathway. These findings provide a new clinical strategy for the prevention of skin photoaging.
BibTeX
@inproceedings{zhang2020concentrated,
  author = {Meng Zhang and Tai Zhang and Yanan Tang and Guiyun Ren and Yanning Zhang and Xiangyu Ren},
  title = {{Concentrated growth factor inhibits UVA-induced photoaging in human dermal fibroblasts via the MAPK/AP-1 pathway}},
  booktitle = {Bioscience},
  year = {2020},
  doi = {10.1042/bsr20193566},
}
Figure